Solid Tumor Clinical Trials

ML28897

A study evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge treatment targeted against certain mutations in cancer patients. Click here to learn more.

MATCH

Molecular Analysis for Therapy Choice (MATCH). Click here to learn more.

STARTRK2

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements. Click here to learn more.

MYPATHWAY

An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents. Click here to learn more.

RXDX105

RXDX105 An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors. Click here to learn more.

UCBC